# The Adult Antiretroviral Treatment and Resistance Study (Tshepo)

> **NCT00197613** · PHASE3 · COMPLETED · sponsor: **Harvard School of Public Health (HSPH)** · enrollment: 650 (—)

## Conditions studied

- AIDS
- HIV Infection

## Interventions

- **DRUG:** (A) zidovudine, lamivudine and nevirapine
- **DRUG:** (B) zidovudine, lamivudine and efavirenz
- **DRUG:** (C) zidovudine, didanosine, and nevirapine
- **DRUG:** (D) zidovudine, didanosine, and efavirenz
- **DRUG:** (E) stavudine, lamivudine, and nevirapine
- **DRUG:** (F) stavudine, lamivudine and efavirenz
- **PROCEDURE:** Adherence Strategy Standard of Care (SOC)
- **PROCEDURE:** Adherence Strategy Community-Based DOT

## Key facts

- **NCT ID:** NCT00197613
- **Lead sponsor:** Harvard School of Public Health (HSPH)
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** —
- **Final completion:** 2007-12
- **Target enrollment:** 650 (—)
- **Last updated:** 2012-09-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00197613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00197613, "The Adult Antiretroviral Treatment and Resistance Study (Tshepo)". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00197613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*